Vibrant Gastro
Drug-free Treatment of Chronic Idiopathic Constipation
Company Overview
Snapshot
Founded in September 2007, Vibrant Gastro operates with 11–50 employees. The company has raised $7.5 million across three funding rounds from four investors, with Unorthodox Ventures leading a Series E round in March 2021. Vibrant Gastro received FDA marketing authorization for its vibrating, drug-free capsule for treating chronic constipation in August 2022.
Business overview
Vibrant Gastro develops drug-free technology systems for gastrointestinal health, primarily focusing on chronic idiopathic constipation. Its core product, the Synchronized Activation Method, utilizes a vibrating capsule to mechanically stimulate the colon and improve natural colonic motility by leveraging the body's biological clock. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Therapeutics, serving patients and healthcare providers.
Strategic signal
In August 2022, Vibrant Gastro secured FDA marketing authorization for its vibrating, drug-free capsule designed to treat chronic constipation. This approval is a significant validation of the company's technology, positioning it for broader market entry in the U.S. and signaling strong commercial potential for its innovative, non-pharmacological approach to a widespread health issue.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory milestone for Vibrant Gastro?
- In August 2022, Vibrant Gastro received FDA marketing authorization for its vibrating, drug-free capsule, enabling its use for treating chronic constipation in the U.S. market.
- What were the results of Vibrant Gastro's Phase 3 clinical trial?
- In May 2022, Vibrant Gastro presented positive Phase 3 data for its drug-free treatment for chronic idiopathic constipation at the 2022 Digestive Disease Week Conference, demonstrating significant improvements in bowel movement frequency, constipation symptoms, and quality of life.
- When did Vibrant Gastro complete its most recent funding round?
- In March 2021, Vibrant Gastro completed a Series E funding round, led by.
- What is the core technology behind Vibrant Gastro's treatment?
- Vibrant Gastro's core technology is a vibrating capsule that uses mechanical stimulation to resynchronize the colon's biological clock, aiming to improve natural colonic motility without drugs.
- When did Vibrant Gastro first conduct clinical studies for its vibrating capsule?
- In October 2017, Vibrant Ltd. successfully completed clinical studies for its intraluminal vibrating capsule, showcasing its efficacy in treating chronic constipation.